Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Medical Oncology 1

Interventions

aprutumab ixadotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Medical Oncology × aprutumab ixadotin × Clear all
NCT02368951 2017-07-12

Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)

Bayer

Phase 1 Terminated
20 enrolled

Medical Oncology

Data powered by HemOnc (CC BY 4.0) Colophon âš¡